These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22926152)

  • 1. Hepatitis: HCV virologic response--new nomenclature recommendations.
    Pol S
    Nat Rev Gastroenterol Hepatol; 2012 Nov; 9(11):619-20. PubMed ID: 22926152
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging antiviral drugs for hepatitis C virus.
    Enomoto M; Tamori A; Kawada N
    Rev Recent Clin Trials; 2009 Sep; 4(3):179-84. PubMed ID: 20028330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of new hepatitis C treatments in different regions of the world.
    Wei L; Lok AS
    Gastroenterology; 2014 May; 146(5):1145-50.e1-4. PubMed ID: 24662488
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of direct antiviral agents in the management of hepatitis C.
    El Kassas M; Elbaz T; Hafez E; Esmat G
    Expert Opin Drug Saf; 2016 Dec; 15(12):1643-1652. PubMed ID: 27661100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly active anti-hepatitis C therapy: seven lessons from HIV.
    Thomas DL
    Antivir Ther; 2012; 17(6 Pt B):1183-8. PubMed ID: 23186629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial investigates two experimental HCV drugs.
    AIDS Patient Care STDS; 2010 Apr; 24(4):270. PubMed ID: 20402017
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of chronic viral hepatitis C with direct acting antiviral agent: review].
    Malov VA; Ubeeva EA; Ubeeva IP; Nikolaev SM; Umbetova KT
    Ter Arkh; 2019 Nov; 91(11):86-89. PubMed ID: 32598617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
    Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C: An unsuspected drug target.
    Murray CL; Rice CM
    Nature; 2010 May; 465(7294):42-4. PubMed ID: 20445618
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs in development for viral hepatitis: care and caution.
    Pockros PJ
    Drugs; 2011 Feb; 71(3):263-71. PubMed ID: 21319865
    [No Abstract]   [Full Text] [Related]  

  • 14. New perspectives in HCV therapy: entry inhibitors.
    Donia M; Cacopardo B; Libra M; Scalia G; McCubrey JA; Nicoletti F
    Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):181-94. PubMed ID: 20497122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 16. New Therapies for Hepatitis C Virus.
    Polenakovik H
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating HCV in HIV 2013: on the cusp of change.
    Martel-Laferrière V; Dieterich DT
    Liver Int; 2014 Feb; 34 Suppl 1():53-9. PubMed ID: 24373079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.
    Preciado MV; Valva P; Escobar-Gutierrez A; Rahal P; Ruiz-Tovar K; Yamasaki L; Vazquez-Chacon C; Martinez-Guarneros A; Carpio-Pedroza JC; Fonseca-Coronado S; Cruz-Rivera M
    World J Gastroenterol; 2014 Nov; 20(43):15992-6013. PubMed ID: 25473152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
    Li DK; Chung RT
    Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.